Xenon Pharmaceuticals

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Xenon Pharmaceuticals excels in epilepsy treatment with strong IP strategy

Xenon Pharmaceuticals demonstrated strong performance and promising efficacy data for XEN1101 in epilepsy treatment, supported by a robust IP strategy and CNS penetration.
While facing challenges in patient enrollment and rising expenses, the company is exploring new therapeutic areas and potential milestone payments through partnerships.
Opportunities lie in expanding XEN1101's market reach, establishing a leadership position in epilepsy treatment, and navigating uncertainties in pediatric indications and generic competition.

Xenon Pharmaceuticals advances epilepsy program amid financial stability and challenges

Xenon Pharmaceuticals showcased progress in their epilepsy program and financial stability, while addressing challenges in enrollment dynamics and competitive pressures.
The company's focus on managing R&D expenses and upcoming milestones reflects a strategic approach to advancing their clinical programs.
Opportunities in the epilepsy market and ongoing formulation development for pediatric patients position Xenon for potential growth and innovation.

Xenon Pharmaceuticals excels in trials and finances, eyes global expansion

Xenon Pharmaceuticals showcases strong performance in key trials and financial stability, supported by positive market reception and strategic leadership additions.
While facing challenges in trial completion and enrollment trends, the company has opportunities to expand market reach, innovate in treatment approaches, and explore global partnerships.
Overall, Xenon's focus on advancing novel therapies for neurological disorders positions it well for future growth and success in the competitive pharmaceutical landscape.

Xenon Pharmaceuticals advances epilepsy and MDD treatments, poised for growth

Xenon Pharmaceuticals showcased strong performance in advancing XEN1101 for epilepsy and MDD treatments, backed by extensive data and strategic partnerships.
While facing challenges in enrollment timelines and technical complexities, the company is well-positioned financially and strategically for future growth.
Opportunities abound in addressing unmet needs, expanding drug applications, and advancing new molecules into clinical development.
Overall, Xenon Pharmaceuticals' Q3 earnings call highlighted a promising outlook for drug development and market positioning.

Xenon Pharmaceuticals excels in Q4, poised for growth in epilepsy and MDD

Xenon Pharmaceuticals showcased strong financials, program advancements, and market insights in Q4 2023, positioning the company well for future growth.
The company's focus on safety, tolerability, and efficacy in MDD treatment, along with leveraging learnings across programs, demonstrates strategic foresight.
While facing challenges in R&D spend allocation and regulatory discussions, Xenon can capitalize on opportunities for operational efficiency and market expansion.
Investor interest in Xenon's pipeline and the potential of its programs in epilepsy and MDD highlight a promising trajectory for the company.

Xenon Pharmaceuticals reports strong Q1 performance and addresses market needs

Xenon Pharmaceuticals is well-positioned with a strong financial base and promising pipeline.
The company faces challenges in conducting well-powered MDD trials and addressing market needs.
Opportunities lie in the substantial unmet need in the major depressive market and azetukalner's potential benefits.
Strategic planning and FDA alignment support Xenon's progress in key therapeutic areas.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xenon to Participate in Fireside Discussion at SVB Leerink 10th Annual Global Healthcare Conference Xenon to Participate in Fireside Discussion at SVB Leerink 10th Annual Global Healthcare Conference

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2020 Financial Results

Pre-Clinical Data Support the Potential Benefit of XEN1101 to Treat Depression and Anhedonia

Xenon Pharmaceuticals Announces Promising New Pre-Clinical Data and Provides Clinical Overview of its XEN1101 Program at ASENT 2021

Early, Promising Data from Physician-Led Phase 2 Open Label Clinical Trial Support XEN007 as a Potential Treatment of Childhood Absence Epilepsy (CAE) Early, Promising Data from Physician-Led Phase 2 Open Label Clinical Trial Support XEN007 as a Potential Treatment of Childhood Absence Epilepsy (CAE)

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at AES2020, the Virtual Annual Meeting of the American Epilepsy Society

Xenon Pharmaceuticals Inc. (XENE) CEO Simon Pimstone on Q3 2020 Results - Earnings Call Transcript

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -66.67% and -36.54%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Lags Revenue Estimates

Shares have risen by 15% since my March recommendation, but EV of around $180 million appears cheap contrasted to multiple opportunities in epilepsy that they are pursuing. I provide a recap of our bullish thesis and multiple management presentations.

Xenon Pharmaceuticals: Updates To Thesis, Low Valuation With Multiple Catalysts In 2021

BURNABY, British Columbia, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it will report its third quarter 2020 financial and operating results after the close of U.S. financial markets on Thursday, November 5, 2020. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update.

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update

Positive Opinion Received Supporting Orphan Medicinal Product Designation in Europe for XEN496 for the Treatment of KCNQ2-DEE Positive Opinion Received Supporting Orphan Medicinal Product Designation in Europe for XEN496 for the Treatment of KCNQ2-DEE

Xenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-DEE Before Year-End

U.S. Food and Drug Administration (FDA) Requests Additional Non-Clinical Data to Support Dose Justification Before Initiation of a Phase II Clinical Trial with NBI-921352 in Pediatric SCN8A-DEE Patients

Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy

BURNABY, British Columbia, Aug.  17, 2020  (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced today the appointment of Dr. Chris Von Seggern as Chief Commercial Officer, effective immediately. In this newly created role, Dr. Von Seggern will report to Dr. Simon Pimstone, Xenon’s Chief Executive Officer, and oversee the commercial strategy and execution for Xenon’s neurology-focused portfolio of therapeutics.

Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial Officer

Xenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q2 2020 Results - Earnings Call Transcript

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 100.00% and 102.79%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals (XENE) Reports Break-Even Earnings for Q2

XEN496 Phase 3 Protocol Submitted to FDA and Trial Initiation Anticipated in 2020

Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

BURNABY, British Columbia, July  30, 2020  (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it will report its second quarter 2020 financial and operating results after the close of U.S. financial markets on Thursday, August 6, 2020. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update.

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update

BELLEVUE, Wash.--(BUSINESS WIRE)--Xenon arc Unveils Groundbreaking Voice of Customer Study Results Focused on Small-to-Mid Sized Business Customers

Xenon arc Unveils Groundbreaking Voice of Customer Study Results Focused on Small-to-Mid Sized Business Customers

LONDON--(BUSINESS WIRE)-- #GlobalXenonFlashLampMarket--The Global Xenon Flash Lamp Market will grow by $ 46.40 mn during 2020-2024

Insights on the Global Xenon Flash Lamp Market 2020-2024 | COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | Technavio

Xenon Pharmaceuticals Inc. (XENE) CEO Simon Pimstone on Q1 2020 Results - Earnings Call Transcript

Progress Reported in Both Proprietary and Partnered Neurology Clinical Programs 

Xenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

Xenon Remains Well-Positioned And Well-Funded Despite COVID-19 Related Setbacks

BURNABY, British Columbia, March  31, 2020  (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today provided a corporate update in the context of the developing situation with the COVID-19 pandemic.

Xenon Pharmaceuticals Provides Corporate Update in the Context of COVID-19

BURNABY, British Columbia, March  26, 2020  (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 63,200 share options. All of the foregoing share options were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of March 25, 2020 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q4 2019 Results - Earnings Call Transcript

Editas Medicine

Roche Holding AG

If you can handle the uncertainty, these small-cap stocks can make you very wealthy.

3 High-Risk, High-Reward Stocks That Have Massive Upside Potential

BURNABY, British Columbia, Feb.  14, 2020  (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that the underwriters of its previously announced public offering of 3,750,000 common shares, which initially closed on January 27, 2020, have exercised in full their option to purchase an additional 562,500 common shares at the public offering price of $16.00 per share, raising additional gross proceeds of $9.0 million and increasing the total gross proceeds of the public offering to $69.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon. 

Xenon Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares

Aurinia Pharmaceuticals

Zymeworks Inc

These developers of drugs for cancer, neurological conditions, and rare diseases may boost risk-taking investors' portfolios.

News for Xenon Pharmaceuticals Stock (XENE)